CENTRAL ADMIXTU
Drug class
Antithrombin Agents
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies. Read more about Antithrombin Agents
164 drugs in this class 74 manufacturers
Drugs in Antithrombin Agents
AA2.5%NO.2 PED-D10-CALCIUM-HEP (amino acid 2.5 % no.2 ped/dextrose 10 %/calcium gluc/heparin)
CALCIUM
CENTRAL ADMIXTU
CENTRAL ADMIXTU
HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine in 0.9 % sodium chloride)
HEPARIN · MAINTAIN PATENCY OF INDWELLING INTRAVENOUS CATHETER
QUVA PHARMA, IN
ARGATROBAN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS IN HEPARIN-INDUCED THROMBOCYTOPENIA ·+2
MYLAN INSTITUTI
ARGATROBAN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS IN HEPARIN-INDUCED THROMBOCYTOPENIA ·+2
WEST-WARD,INC./
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
FRESENIUS KABI
FONDAPARINUX SODIUM
HEPARIN · ACUTE PULMONARY THROMBOEMBOLISM ·+6
EUGIA US LLC
CENTRAL ADMIXTU
Filter & compare in the drug finder →
Opens the drug finder with Antithrombin Agents preselected. Add indication or manufacturer filters there.
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies.
In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation.
In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specialized thromboembolic disorders.
-
fda.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specia...
-
nih.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specia...
-
nih.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
-
fda.gov
In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
-
drugbank.com
In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
-
fda.gov
In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specialized thromboembolic disorders
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.